Vivoryon Therapeutics Revenue vs. Cash Flow From Operations

VVY Stock   1.96  0.04  2.00%   
Based on Vivoryon Therapeutics' profitability indicators, Vivoryon Therapeutics NV may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Vivoryon Therapeutics' ability to earn profits and add value for shareholders.
For Vivoryon Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Vivoryon Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Vivoryon Therapeutics NV utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Vivoryon Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Vivoryon Therapeutics NV over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Please note, there is a significant difference between Vivoryon Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vivoryon Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vivoryon Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Vivoryon Therapeutics Cash Flow From Operations vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Vivoryon Therapeutics's current stock value. Our valuation model uses many indicators to compare Vivoryon Therapeutics value to that of its competitors to determine the firm's financial worth.
Vivoryon Therapeutics NV is rated first in revenue category among its peers. It is rated first in cash flow from operations category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vivoryon Therapeutics' earnings, one of the primary drivers of an investment's value.

Vivoryon Revenue vs. Competition

Vivoryon Therapeutics NV is rated first in revenue category among its peers. Market size based on revenue of Biotechnology industry is at this time estimated at about 2.12 Billion. Vivoryon Therapeutics maintains roughly 10.76 Million in revenue contributing less than 1% to stocks in Biotechnology industry.

Vivoryon Cash Flow From Operations vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Vivoryon Therapeutics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
10.76 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Vivoryon Therapeutics

Operating Cash Flow

 = 

EBITDA

-

Taxes

 = 
(11.26 M)
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.

Vivoryon Cash Flow From Operations Comparison

Vivoryon Therapeutics is currently under evaluation in cash flow from operations category among its peers.

Vivoryon Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Vivoryon Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Vivoryon Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Vivoryon Therapeutics' important profitability drivers and their relationship over time.

Use Vivoryon Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vivoryon Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vivoryon Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Vivoryon Therapeutics Pair Trading

Vivoryon Therapeutics NV Pair Trading Analysis

The ability to find closely correlated positions to Vivoryon Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vivoryon Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vivoryon Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vivoryon Therapeutics NV to buy it.
The correlation of Vivoryon Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vivoryon Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vivoryon Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vivoryon Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Vivoryon Therapeutics position

In addition to having Vivoryon Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run JPY Crypto Assets Thematic Idea Now

JPY Crypto Assets
JPY Crypto Assets Theme
An experimental p2p digital currency that is accepted by many vendors in Japanese Yen. The JPY Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize JPY Crypto Assets Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Vivoryon Stock Analysis

When running Vivoryon Therapeutics' price analysis, check to measure Vivoryon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivoryon Therapeutics is operating at the current time. Most of Vivoryon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivoryon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivoryon Therapeutics' price. Additionally, you may evaluate how the addition of Vivoryon Therapeutics to your portfolios can decrease your overall portfolio volatility.